Expression of c-erbB2 in gestational trophoblastic disease and its clinical significance

Abstract

In order to explore a potential indicator of predicting the occurrence and development of gestational trophoblastic tumor, the expression of c-erbB2 oncogene in human normal placenta, hydatidiform mole and choriocarcinoma was investigated. The expression of c-erbB2 was detected immunohistochemically by monoclonal antibody against the gene on the formalin-fixed paraffin sections of 21 hydatidiform moles, 21 invasive moles, 20 choriocarcinomas and 30 normal placentas. Results showed that the expression level of c-erbB2 was significantly higher in gestational trophoblastic tumor than in hydatidiform mole and normal placenta of midterm and term pregnancy (P<0.05), while there was no significant difference between patients with gestational trophoblastic tumor of stage III, IV and those of stage I, II. It was demonstrated that overexpression of c-erbB2 may closely associated with malignant transformation of hydatidiform mole, not only providing important insight into pathogenesis of gestational trophoblastic tumor, but also having an important significance for the early diagnosis and early treatment of gestational trophoblastic tumor.

Keywords

c-erbB2 oncogene / placenta / trophoblastic tumor

References

[1] PitotH C, HikitaH, DraganY, et al. . Review article: the stages of gastrointestinal carcinogenesis—application of rodent models to human disease. Aliment Pharmacol Ther, 2000, 14(Suppl 1): 153-153

[2] SenT C, GossP E. Characterization of a repressor element and a juxtaposed tissue restricted activator element located on the dital new gene promoter. J Biol Chem, 2000, 275(9): 6600-6600

[3] PegramM, SlamonD. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol, 2000, 27(5 Suppl 9): 13-13

[4] WilliamsG T, SmithC A. Molecular regulation of apoptosis: Genetic controls on cell death. Cell, 1993, 74777-777

[5] PavazziniF, MangiliG, BelloniC, et al. . The problem of identification of prognostic factors for persistent trophoblastic disease. Gynecol Oncol, 1988, 3057-57

[6] CameronB, GownA M, TamimiH K. Expression of c-erbB2 oncogence product in persistent gestational trophoblastic disease. Am J Obstet Gynecol, 1994, 170(6): 1616-1616

[7] FulopV, MokS C, GenestD R, et al. . c-myc, c-erbB2, c-fms and bcl-2 oncoproteins expression in normal placenta, partial and complete mole and choriocarcinoma. J Repro Med, 1998, 43(2): 101-101

[8] SarkerS, BarryM, KacinskiM D, et al. . Demonstration of myc and ras oncogene expression by hybridization in situ in hydatidiform mole and in the BeWo Chorjocarcinoma cell line. Am J Obstet Gynecol, 1986, 154(2): 390-390